Actelion Ltd. Swings to Profit, Key Drug Tracleer Disappoints

ZURICH, April 22 (Reuters) - Swiss biotech company Actelion Ltd swung to a first-quarter net profit of 48 million Swiss francs ($47.43 million), but results were hit by the weak dollar and sales of key drug Tracleer disappointed.

MORE ON THIS TOPIC